1 / 13

What is Acute Insomnia?

Characterized by: 1,2 Sudden onset Short course (duration ≤3 months) Patient may experience: Difficulty initiating sleep Sleep fragmentation Increased duration of nocturnal awakenings Short duration of sleep Poor sleep quality . What is Acute Insomnia?.

qamar
Télécharger la présentation

What is Acute Insomnia?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Characterized by:1,2 • Sudden onset • Short course (duration ≤3 months) • Patient mayexperience: • Difficulty initiating sleep • Sleep fragmentation • Increased duration of nocturnal awakenings • Short duration of sleep • Poor sleep quality What is Acute Insomnia? American Academy of Sleep Medicine. ICSD-2 – International Classification of Sleep Disorders, 2nd ed: Diagnostic and coding manual. 2005. Alberta Medical Association. Toward Optimized Practice (TOP) Adult Insomnia: Diagnosis to Management Clinical Practice Guidelines. 2010.

  2. Early therapy can prevent the evolution of more complex sleep-related syndromes • Recurrent, untreated insomnia may lead to more chronic, intractable insomnia • Patient may develop psychophysiological (conditioned) insomnia over time; more difficult to resolve1 • Bidirectional link between insomnia and depression2 Why Treat Insomnia? Drake CL, Roth T. Sleep Med Clin. 2006;1:333-349. StanerL. Sleep Med Rev. 2010;14:35-46.

  3. Predisposing factors • Precipitatingfactors • Perpetuatingfactors Key Features to Assessment: 3 “P’s”

  4. Predisposing Factors to Insomnia • .

  5. Most common is emotional distress • Bereavement • Relationship difficulties • Loss of work • Financial burdens • Particular stressors (school examinations, work projects, etc.) • Changes in medication or dosing • Onset of medical or psychiatric disorder or another primary sleep disorder Precipitating Factors for Insomnia

  6. Complex interaction between behavioural, emotional, and cognitive factors • Behavioural issues are typically the easiest to address • Cognitive and emotional elements may require specialized therapies and techniques Perpetuating Factors for Insomnia

  7. Primary goals • to improve sleep quality and quantity • to improve insomnia-related daytime impairments • Reassess therapy every few weeks and/or monthly until insomnia appears stable or resolves • Follow-up every 6 months thereafter to avoid relapse1 • If a single treatment is ineffective, try other options, a combination of therapies,2 or test for comorbidities Management Strategies Schutte-Rodin S et al. J Clin Sleep Med. 2008;4(5):487-504. ZavesickaL et al. NeuroEndocrinolLett. 2008;29(6):895-901.

  8. Important first step to determine management • Engages patients in the treatment process • Provides data on severity, regularity, and compounding influences • Patient instructed to record sleep daily over 1–2 weeks • Review diary entries on follow-up appointment Sleep Diary

  9. Overcoming Maladaptive Compensatory Behavioural Responses

  10. Pharmacotherapy • Accompany with patient education • treatment goals and expectations • safety concerns • potential adverse events and drug interactions • other treatment modalities (cognitive and behavioural treatments) • potential for dosage escalation • rebound insomnia Health Canada. Authorized Sleep-Aid Medications in Canada.

  11. Cautions Related to Medications Commonly Prescribed in the Acute Management of Insomnia

  12. Short-term Therapies: Effective and Safe First- and Second-line Options * There is a moderate level of evidence and the extent of present use support the use of trazodone as a second-line agent

  13. “Natural” Agents and Over-the-counter Products Used as Sleep Aids

More Related